Publications by authors named "Jan Torzewski"

Claim this Profile
S
Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective international randomized controlled trial.
Jan Torzewski, Stephan Mattecka, Benjamin Mayer, Gregg W Stone, Ahmed Sheriff

Coron Artery Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I study.
Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Bert Ferdinande

EuroIntervention· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Coronary Physiology by μFR Measurement After DREAMS-3G-Scaffold Implantation.
Hector M Garcia-Garcia, Ryan L Wallace, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski

JACC Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months.
Alp Aytekin, Masaru Seguchi, Erion Xhepa, Michael Haude, Adrian Wlodarczak, Jan Torzewski

Catheter Cardiovasc Interv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial: Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design.
Jan Torzewski, Ahmed Sheriff, Janos G Filep, Karlheinz Peter, Paul M Ridker

Front Cardiovasc Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.
Masaru Seguchi, Alp Aytekin, Erion Xhepa, Michael Haude, Adrian Wlodarczak, Jan Torzewski

EuroIntervention· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.
Hector M Garcia-Garcia, Ron Waksman, Gebremedhin D Melaku, Mohil Garg, Solomon Beyene, Jan Torzewski

Eur Heart J Cardiovasc Imaging· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Bert Ferdinande

EuroIntervention· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique.
Gregg W Stone, Dean J Kereiakes, Tommaso Gori, D Christopher Metzger, Bernardo Stein, Jan Torzewski

J Am Coll Cardiol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance.
Agneta Virbickiene, Tomas Lapinskas, Christoph D Garlichs, Stephan Mattecka, Radu Tanacli, Jan Torzewski

J Cardiovasc Dev Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry.
Adrian Wlodarczak, Piero Montorsi, Jan Torzewski, Johan Bennett, Gregory Starmer

EuroIntervention· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.
Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Bert Ferdinande

EClinicalMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustainability of C-Reactive Protein Apheresis in Acute Myocardial Infarction-Results from a Supplementary Data Analysis of the Exploratory C-Reactive Protein in Acute Myocardial Infarction-1 Study.
Horst Skarabis, Jan Torzewski, Wolfgang Ries, Franz Heigl, Christoph D Garlichs

J Clin Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Difference in 30-Day Outcome and Quality of Life in Transradial Versus Transfemoral Access - Results From the German Austrian ABSORB Registry (GABI-R).
Bastian Wein, Myron Zaczkiewicz, Matthias Graf, Oliver Zimmermann, Tommaso Gori, Jan Torzewski

Cardiovasc Revasc Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance.
Johan Bennett, Alfonso Ielasi, Jan Torzewski, Quentin de Hemptinne, Enrico Cerrato

Cardiovasc Revasc Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS).
Myron Zaczkiewicz, Katharina Kostenzer, Matthias Graf, Benjamin Mayer, Oliver Zimmermann, Jan Torzewski

J Clin Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons.
Jan Torzewski, Patrizia Brunner, Wolfgang Ries, Christoph D Garlichs, Stefan Kayser

J Clin Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry.
Christian Schumann, Franz Heigl, Imanuel J Rohrbach, Ahmed Sheriff, Lutz Wagner, Jan Torzewski

Am J Case Rep· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Treatment of a 39-Year-Old COVID-19 Patient with Respiratory Failure by Selective C-Reactive Protein Apheresis.
Jan Torzewski, Oliver Zimmermann, Stefan Kayser, Franz Heigl, Florian Wagner

Am J Case Rep· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.
Stefan Verheye, Adrian Wlodarczak, Piero Montorsi, Jan Torzewski, Johan Bennett

Catheter Cardiovasc Interv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study.
Wolfgang Ries, Jan Torzewski, Franz Heigl, Christian Pfluecke, Sebastian Kelle

Front Cardiovasc Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.
Jan Torzewski, Franz Heigl, Oliver Zimmermann, Florian Wagner, Christian Schumann

Am J Case Rep· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R).
Myron Zaczkiewicz, Bastian Wein, Matthias Graf, Oliver Zimmermann, Johannes Kastner, Jan Torzewski

Int J Cardiol Heart Vasc· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry.
Stefan Verheye, Adrian Wlodarczak, Piero Montorsi, Johan Bennett, Jan Torzewski

EuroIntervention· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective C-Reactive Protein-Apheresis in Patients.
Wolfgang Ries, Franz Heigl, Christoph Garlichs, Ahmed Sheriff, Jan Torzewski

Ther Apher Dial· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis